Alkem Labs launches epilepsy drug Perampil in India

Published On 2021-06-11 06:30 GMT   |   Update On 2021-06-11 12:34 GMT
Advertisement

Mumbai: Drugmaker, Alkem Laboratories, has recently announced the launch of Perampil (Perampanel) tablets 2 mg/4 mg/6 mg in India.

Alkem has launched Perampil, at 2 mg – Rs. 49/strip of 7 tablets, 4 mg – Rs. 180/strip of 15 tablets and 6 mg – Rs. 300/strip of 15 tablets.

"This product reaffirms Alkem's commitment towards improving epilepsy care by bringing multiple treatment options of quality products to patients and health care professionals in India," the company stated.

Advertisement

Alkem had also launched Brivasure (Brivaracetam) tablets in March 2021 for the adjunctive management of partial onset seizure with or without secondary generalization.

The drug, Perampanel, has been approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial onset seizures in patients with epilepsy aged 4 years and older and also as an adjunctive therapy in treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.

Established in 1973 and headquartered in Mumbai, Alkem is a Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets.




Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News